{"id":17729,"date":"2022-11-21T09:23:07","date_gmt":"2022-11-21T09:23:07","guid":{"rendered":"https:\/\/touchrespiratory.com\/?post_type=media_gallery&p=17729"},"modified":"2022-12-14T10:28:27","modified_gmt":"2022-12-14T10:28:27","slug":"jean-elwing-chest-2022-inhaled-treprostinil-for-pulmonary-hypertension-due-to-interstitial-lung-disease-the-increase-ole-study","status":"publish","type":"media_gallery","link":"https:\/\/touchrespiratory.com\/interstitial-lung-disease\/conference-hub\/jean-elwing-chest-2022-inhaled-treprostinil-for-pulmonary-hypertension-due-to-interstitial-lung-disease-the-increase-ole-study\/","title":{"rendered":"Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study"},"content":{"rendered":"
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316<\/a>), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing<\/strong> (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the INCREASE OLE study.<\/p>\n